Glycostem has an experienced supervisory board consisting of three members:
Chairman and Chief Executive Officer, Troels Jordansen, started his career in healthcare with Leo Pharmaceutical Product and after 4 years with Johnson & Johnson Orthopaedics was one of the initial Genzyme Europe hires to focus on commercialising Carticel and Epicel in 1996. Over the last 20 years Troels has worked for 5 different cellular therapy companies including Dutch IsoTis NV, Australian Clinical Cell Culture Pty Ltd and British Azellon Ltd. where he was a co-founder. Troels roles have covered sales, marketing and general management and the last 15 years as Managing Director and/or Chairman for private and public listed companies. Troels has been part of award winning management teams raising over €150 million. Troels became Chairman of Glycostem in January 2014 and CEO in July 2016.
Jan van der Hoeven is an investor in the field of Life Sciences. He has more than 25 years of operating, scientific and financial experience in private equity backed life sciences companies. He has been involved in a number of successful international merger & acquisition deals. He is active in a number of funds to stimulate Life Sciences Companies.
Dirk Groenewegen has a masters' degree in chemical engineering and a PhD in microbiology. After an international career as senior R&D-manager in pharmaceutical and chemical multinationals Dirk became a license mediation and new-business consultant, now with 20+ years' experience. Dirk is an active participant in many international networks, like the Licensing International Society, the Parental Drug Association and various organizations involved in Hematology & Oncology. In 2007 Dirk founded Glycostem Therapeutics, which he served as CEO for 7 years.